Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 28;16(12):e0261923.
doi: 10.1371/journal.pone.0261923. eCollection 2021.

Quantitative cytokine level of TNF-α, IFN-γ, IL-10, TGF-β and circulating Epstein-Barr virus DNA load in individuals with acute Malaria due to P. falciparum or P. vivax or double infection in a Malaria endemic region in Indonesia

Insani Budiningsih  1 , Yoes Prijatna Dachlan  2 , Usman Hadi  3 , Jaap Michiel Middeldorp  4
Affiliations

Quantitative cytokine level of TNF-α, IFN-γ, IL-10, TGF-β and circulating Epstein-Barr virus DNA load in individuals with acute Malaria due to P. falciparum or P. vivax or double infection in a Malaria endemic region in Indonesia

Insani Budiningsih et al. PLoS One. .

Abstract

Plasmodium falciparum Malaria and Epstein-Barr Virus (EBV) infection are risk factors in the development of Burkitt's lymphoma. In Indonesia, 100% of the population is persistently infected with EBV early in life and at risk of developing EBV-linked cancers. Currently, 10.7 million people in Indonesia are living in Malaria-endemic areas. This cross-sectional study was initiated to investigate how acute Malaria dysregulates immune control over latent EBV infection. Using blood and plasma samples of 68 patients with acute Malaria and 27 healthy controls, we measured the level of parasitemia for each plasmodium type (P. falciparum, P. vivax, and mixed) by microscopy and rapid test. The level of 4 regulatory cytokines was determined by quantitative ELISA and the level of circulating EBV genome by real-time PCR targeting the single copy EBNA-1 sequence. All Plasmodium-infected cases had high-level parasitemia (>1000 parasites/ul blood) except for one case. EBV-DNA levels were significantly more elevated in P. falciparum and P. vivax infections (P<0.05) compared to controls. EBV-DNA levels were not related to age, gender, Malaria symptoms, or plasmodium type. TNF-α and IL-10 levels were increased in Malaria cases versus controls, but IFN-γ and TGF- β levels were comparable between the groups. Only TNF-α levels in P. falciparum cases showed a clear correlation with elevated EBV DNA levels (R2 = 0.8915). This is the first study addressing the relation between EBV (re)activation and cytokine responses during acute Malaria, revealing a clear correlation between pro-inflammatory cytokine TNF-α and EBV-DNA levels, specifically in P. falciparum cases, suggesting this cytokine to be key in dysregulating EBV homeostasis during acute P. falciparum Malaria.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Parasitemia levels of Malaria cases infected with P. falciparum (n = 26), P. vivax (n = 28) and Mixed parasites (n = 14).
Fig 2
Fig 2. Quantitative EBV-DNA genome levels (copies/ml) in blood plasma in 3 groups of Malaria cases (P. falciparum, P. vivax and Mixed) and regional controls.
Box-limits represent the 95% confidence interval and the line represents the median level of EBV-DNA. Statistical analysis was done by one-Way ANOVA (cases versus controls).
Fig 3
Fig 3
Comparison of Parasitemia versus EBV genome levels in Malaria cases; (a) P. falciparum, (b) P. vivax, (c) Mixed. Statistical analysis (R2) was done by linear regression.
Fig 4
Fig 4
Quantitative cytokine levels in Malaria cases and controls; (a) TNF-α, (b) IL-10, (c) IFN-γ and (d) TGF-β. Statistical analysis was done by One-Way ANOVA for cases versus controls.
Fig 5
Fig 5
Comparison of circulating EBV genome levels and cytokine levels in (a) P. falciparum cases, (b) P. vivax cases, (c) Mixed cases and (d) healthy controls. Statistical analysis was done by linear regression.
See this image and copyright information in PMC

References

    1. Thorley-Lawson DA. Epstein-Barr Virus: Introducing the virus. Curr Top Microbiol Immunol.2015;390(1):151–209. doi: 10.1007/978-3-319-22822-8_8 . - DOI - PMC - PubMed
    1. Odumade OA, Hogquist KA, Balfour HH. Progress and problems in understanding and managing primary Epstein-Barr Virus infections. Clin Microbiol Rev. 2011; 24(1):193–209. doi: 10.1128/CMR.00044-10 . - DOI - PMC - PubMed
    1. Hochberg D, Middeldorp JM, Catalina M, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. Demonstration of the Burkitt’s lymphoma Epstein-Barr Virus phenotype in dividing latently infected memory cells in vivo. Proc Natl Acad Sci USA. 2004; 101(1):239–44. doi: 10.1073/pnas.2237267100 . - DOI - PMC - PubMed
    1. Middeldorp JM, Brink AATP, Van den Brule AJC, Meijer CJLM. Pathogenic roles for Epstein-Barr Virus (EBV) gene products in EBV-associated proliferative disorders. Crit Rev Oncol Hematol. 2003; 45(1):1–36. doi: 10.1016/s1040-8428(02)00078-1 . - DOI - PubMed
    1. Kutok JL and Wang F. Spectrum of Epstein-Barr virus-associated diseases. Annu Rev Pathol. 2006; 1:375–404. doi: 10.1146/annurev.pathol.1.110304.100209 . - DOI - PubMed

MeSH terms